文献速递临床试验与 GCP真实世界研究与卫生经济

远程(远程医疗和在线)认知行为疗法治疗高影响慢性疼痛与常规照护的临床和成本效果比较:RESOLVE多中心随机对照试验研究方案

Comparing the clinical and cost-effectiveness of remote (telehealth and online) cognitive behavioral therapy-based treatments for high-impact chronic pain relative to usual care: study protocol for the RESOLVE multisite randomized control trial.
PubMed 文献 · Trials · 2023-03-16

RESOLVE试验为比较效果的三臂随机对照试验,在4个大型整合医疗系统开展,比较专业电话/视频认知行为疗法、在线疼痛TRAINER项目与常规照护加书面指南,随访1年,主要结局为3个月疼痛严重程度的最小临床重要差异(≥30%减轻),并评估成本效果,结局评估对分组设盲。

要点

  • 试验比较电话/视频认知行为疗法、在线疼痛TRAINER与常规照护加书面指南三种策略。
  • 主要结局为3个月疼痛严重程度(疼痛强度和疼痛相关干扰复合)≥30%减轻。
  • 随访1年,评估成本效果,结局评估对分组设盲。

核心结论

  • 该大规模试验为严格评估和比较两种相对低成本、可扩展的认知行为疗法治疗高影响慢性疼痛的临床和成本效果提供了独特机会。

研究设计与样本

  • 比较效果的三臂随机对照试验,在位于明尼苏达州、佐治亚州、俄勒冈州和华盛顿州的4个大型整合医疗系统开展,纳入城乡不同人群。
  • 比较(1)8次一对一专业电话/视频认知行为疗法项目;(2)先前开发并测试的8次在线认知行为疗法项目(疼痛TRAINER);(3)常规照护加慢性疼痛管理书面指南。
  • 分配后随访1年,在基线及分配后3、6、12个月评估。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要结局为3个月时疼痛严重程度(疼痛强度和疼痛相关干扰的复合)的最小临床重要差异(≥30%减轻),采用改良11项简明疼痛量表-简表评估。
  • 次要结局包括3、6、12个月时疼痛严重程度、疼痛强度、疼痛相关干扰评分、生活质量指标和患者总体变化印象。
  • 成本效果通过每增加一名达到主要结局最小临床重要差异的患者所需增量成本以及每获得一个质量调整生命年的成本评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cognitive behavioral therapy for chronic pain (CBT-CP) is an effective but underused treatment for high-impact chronic pain. Increased access to CBT-CP services for pain is of critical public health importance, particularly for rural and medically underserved populations who have limited access due to these services being concentrated in urban and high income areas. Making CBT-CP widely available and more affordable could reduce barriers to CBT-CP use. METHODS: As part of the National Institutes of Health Helping to End Addiction Long-term® (NIH HEAL) initiative, we designed and implemented a comparative effectiveness, 3-arm randomized control trial comparing remotely delivered telephonic/video and online CBT-CP-based services to usual care for patients with high-impact chronic pain. The RESOLVE trial is being conducted in 4 large integrated healthcare systems located in Minnesota, Georgia, Oregon, and Washington state and includes demographically diverse populations residing in urban and rural areas. The trial compares (1) an 8-session, one-on-one, professionally delivered telephonic/video CBT-CP program; and (2) a previously developed and tested 8-session online CBT-CP-based program (painTRAINER) to (3) usual care augmented by a written guide for chronic pain management. Participants are followed for 1 year post-allocation and are assessed at baseline, and 3, 6, and 12 months post-allocation. The primary outcome is minimal clinically important difference (MCID; ≥ 30% reduction) in pain severity (composite of pain intensity and pain-related interference) assessed by a modified 11-item version of the Brief Pain Inventory-Short Form at 3 months. Secondary outcomes include pain severity, pain intensity, and pain-related interference scores, quality of life measures, and patient global impression of change at 3, 6, and 12 months. Cost-effectiveness is assessed by incremental cost per additional patient with MCID in primary outcome and by cost per quality-adjusted life year achieved. Outcome assessment is blinded to group assignment. DISCUSSION: This large-scale trial provides a unique opportunity to rigorously evaluate and compare the clinical and cost-effectiveness of 2 relatively low-cost and scalable modalities for providing CBT-CP-based treatments to persons with high-impact chronic pain, including those residing in rural and other medically underserved areas with limited access to these services. TRIAL REGISTRATION: ClinicalTrials.gov NCT04523714. This trial was registered on 24 August 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mayhew M, Balderson BH, Cook AJ, et al. Comparing the clinical and cost-effectiveness of remote (telehealth and online) cognitive behavioral therapy-based treatments for high-impact chronic pain relative to usual care: study protocol for the RESOLVE multisite randomized control trial. Trials. 2023. PMID: 36927459. doi:10.1186/s13063-023-07165-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。